S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
LON:SAR

Sareum (SAR) Share Price, News & Analysis

GBX 10.75
-3.75 (-25.86%)
(As of 03/28/2024 ET)
Today's Range
10
12.20
50-Day Range
14
53.50
52-Week Range
10.50
149
Volume
7.62 million shs
Average Volume
316,927 shs
Market Capitalization
£7.71 million
P/E Ratio
N/A
Dividend Yield
1.10%
Price Target
GBX 304

Sareum MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,761.2% Upside
GBX 304 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.69 out of 5 stars

SAR stock logo

About Sareum Stock (LON:SAR)

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancerandcancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.

SAR Stock Price History

SAR Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Sareum Holdings plc (LON:SAR): Are Analysts Optimistic?
Sareum Holdings PLC (RYH0.SG)
Sareum surges as partner agrees licence for promising molecule
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Sareum shares just jumped 22%! Here’s why
See More Headlines
Receive SAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 304
High Stock Price Target
GBX 304
Low Stock Price Target
GBX 304
Potential Upside/Downside
+2,666.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
£-3,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£47,204.00
Cash Flow
GBX 0.97 per share
Book Value
GBX 2 per share

Miscellaneous

Free Float
N/A
Market Cap
£7.89 million
Optionable
Not Optionable
Beta
-0.69
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Timothy John Mitchell Ph.D. (Age 64)
    Founder, CEO & Executive Director
    Comp: $207.85k
  • Dr. John Charles Reader Ph.D. (Age 57)
    Founder, Chief Scientific Officer & Executive Director
    Comp: $205.8k
  • Mr. Clive H. W. Birch F.C.A. (Age 70)
    Senior Independent Non-Executive Director & Secretary
    Comp: $25k
  • Alexandra Harrison
    Head of IR

SAR Stock Analysis - Frequently Asked Questions

Should I buy or sell Sareum stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sareum in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SAR shares.
View SAR analyst ratings
or view top-rated stocks.

What is Sareum's stock price target for 2024?

1 equities research analysts have issued 12-month price targets for Sareum's shares. Their SAR share price targets range from GBX 304 to GBX 304. On average, they predict the company's share price to reach GBX 304 in the next year. This suggests a possible upside of 2,761.2% from the stock's current price.
View analysts price targets for SAR
or view top-rated stocks among Wall Street analysts.

How have SAR shares performed in 2024?

Sareum's stock was trading at GBX 59.50 at the beginning of the year. Since then, SAR shares have decreased by 82.1% and is now trading at GBX 10.63.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Sareum own?
How do I buy shares of Sareum?

Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:SAR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners